Overexpression of wild type KRAS increased the IC50 (inhibitory concentration of drug that decreases cell viability to 50%) to crizotinib from 0.16 μM to 1.68 μM (p-value < 0.001) (Figure 4A, ,4G)4G) and NF1 downregulation increased the IC50 to crizotinib from 0.16 μM to 0.75 μM (p-value < 0.001) (Figure 4D, ,4H).4H). Treatment of cells harboring both METex14 and KRAS overexpression with the combination of crizotinib and the MEK inhibitor trametinib in order to block both MET signaling and downstream MAPK pathway signaling restored sensitivity to treatment (crizotinib IC50 of 1.68 μM in the absence of trametinib versus 0.25 μM with trametinib co-treatment, p-value < 0.001) (Figure 4B, ,4G).4G). Similarly, co-treatment of cells harboring both METex14 and NF1 downregulation with both trametinib and crizotinib restored sensitivity to treatment (crizotinib monotherapy IC50 0.75 μM versus 0.18 μM upon addition of trametinib, p-value < 0.001 (Figure 4E, ,4H).4H). The selected trametinib dose modestly reduced but did not eliminate cell growth in the absence of crizotinib (Supplemental Figure S5). Immunoblotting demonstrated sustained Erk phosphorylation despite crizotinib treatment in samples with KRAS overexpression or NF1 downregulation, which was abrogated by the addition of trametinib (Figure 4C, ,4F).4F). In both genomic contexts, combination treatment was associated with increased levels of cleaved PARP, indicative of apoptosis, which was absent with monotherapy (Figure 4C, ,4F4F).
建设性意见 |
父亲的治疗传来了好消息
父亲今年68岁，从今年三月低确认肺癌晚期到现在，一直没有好消息。胸水基因检测：EGFR
HER2突变肺癌诊疗实现新突破，HER2检
作者：seacat
近几年来靶向和免疫疗法的发展显著改善了肺癌患者的生存期，但仍有一部
安禹堂产品真实反馈
患友使用安禹堂皮肤抑菌液、手足平、甲沟炎凝胶真实反馈
中日友好医院科研转化产品安
肺腺癌egfr21-l858r突变，egfr扩增、
老爸21年3月发现肺腺癌晚期，双肺转移，纵隔淋巴结增大，取组织基因检测结果为egfr21-
【跨越五年】可能是最轻松治疗的肺癌
转载自：Mia和小怪兽
现在刚好距离我爸发现肺癌过去五年了，跟大部分患者比，我爸应
显身卡
